Ignite Creation Date:
2025-12-25 @ 12:05 AM
Ignite Modification Date:
2026-02-23 @ 8:07 PM
Study NCT ID:
NCT01900158
Status:
COMPLETED
Last Update Posted:
2019-10-29
First Post:
2013-05-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
Sponsor:
PCI Biotech AS
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Cholangiocarcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Phase I | View |
| None | CCA | View |
| None | Cholangiocarcinoma | View |
| None | bile duct cancer | View |
| None | klatskin | View |
| None | perihilar | View |
| None | Amphinex | View |
| None | Gemcitabine | View |
| None | Photochemical internalisation | View |
| None | Safety | View |
| None | Tolerability | View |
| None | Efficacy | View |
| None | Cisplatin | View |
| None | PCI | View |
| None | extrahepatic | View |
| None | local control | View |
| None | local tumour treatment | View |
| None | biliary | View |
| None | fimaporfin | View |